Bajaj Healthcare Reports Q2 FY26 Revenue of ₹1,470.49 Crore, PAT at ₹1,110.92 Crore

Bajaj Healthcare Limited , a prominent player in the pharmaceutical sector, has announced its financial results for the second quarter of fiscal year 2026, showcasing robust performance despite challenging market conditions.

Key Financial Highlights

Particulars (₹ in Crore)	Q2 FY26	Q2 FY25	YoY Change	H1 FY26	H1 FY25	YoY Change
Revenue from Operations	1,470.49	1,300.89	13.04%	2,967.51	2,053.59	44.50%
Total Income	1,495.68	1,356.06	10.30%	2,992.61	2,087.97	43.33%
EBITDA	2,861.29	2,592.49	10.37%	5,398.02	5,735.95	-5.89%
Profit Before Tax	1,596.21	1,244.85	28.22%	3,048.72	2,263.26	34.70%
Profit After Tax	1,110.92	946.49	17.37%	2,294.29	1,659.62	38.24%
EPS (Basic) in ₹	3.53	3.36	5.06%	7.27	5.95	22.18%

Operational Performance

Bajaj Healthcare demonstrated strong growth in the second quarter of FY26, with revenue from operations reaching ₹1,470.49 crore, marking a 13.04% increase compared to the same quarter last year. The company's total income for Q2 FY26 stood at ₹1,495.68 crore, up by 10.30% year-on-year.

The company's profitability showed significant improvement, with profit before tax (PBT) increasing by 28.22% to ₹1,596.21 crore in Q2 FY26, compared to ₹1,244.85 crore in Q2 FY25. Profit after tax (PAT) rose by 17.37% to ₹1,110.92 crore, reflecting the company's ability to maintain profitability amidst market challenges.

Half-Yearly Performance

For the first half of FY26, Bajaj Healthcare reported impressive growth in its financials. Revenue from operations surged by 44.50% to ₹2,967.51 crore, compared to ₹2,053.59 crore in H1 FY25. The company's PAT for H1 FY26 stood at ₹2,294.29 crore, a substantial increase of 38.24% from the previous year.

Earnings Per Share and Equity

The company's earnings per share (EPS) for Q2 FY26 improved to ₹3.53, up from ₹3.36 in the same quarter last year. For H1 FY26, the EPS reached ₹7.27, showcasing a robust 22.18% growth compared to H1 FY25.

As of September 30, 2025, Bajaj Healthcare's total equity stood at ₹48,639.34 crore, with a share capital of ₹1,579.16 crore and other equity of ₹47,060.18 crore.

Discontinued Operations

The company reported a loss of ₹133.94 crore from discontinued operations for the quarter. This is related to the company's decision in the previous fiscal year to sell or dispose of certain undertakings and industrial lands.

Corporate Actions

In April 2025, Bajaj Healthcare acquired Genrx Pharmaceuticals Private Limited (in Liquidation) for a total consideration of ₹1,085 lakhs. The company has filed an application with the National Company Law Tribunal (NCLT) in Mumbai for necessary reliefs and concessions for the effective implementation of this acquisition.

Conclusion

Bajaj Healthcare's Q2 FY26 results demonstrate the company's resilience and growth potential in the pharmaceutical sector. With strong revenue growth and improved profitability, the company appears well-positioned to capitalize on market opportunities and navigate challenges in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.04%	+0.16%	+8.34%	-24.53%	+24.73%	+29.37%

Bajaj HealthCare Limited (BHL) has achieved a significant milestone in its pharmaceutical development journey. The company has received a positive recommendation from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Suvorexant Tablets in India.

Key Highlights

Bajaj Healthcare is the first company in India to receive regulatory clearance for Suvorexant
The drug will be tested in tablet strengths of 5 mg, 10 mg, 15 mg, and 20 mg
Suvorexant is a prescription medication used to treat insomnia in adults
Phase III trials will assess efficacy, safety, and tolerability before regulatory submission

Trial Details and Future Plans

The upcoming Phase III trials represent a crucial step in Bajaj Healthcare's drug development process. These trials will evaluate Suvorexant's effectiveness and safety profile in a diverse patient population. Upon successful completion, the company plans to seek marketing authorization in select markets, paving the way for commercial launch.

Management Commentary

Mr. Anil Jain, Managing Director of Bajaj Healthcare Limited, expressed confidence in the company's capabilities, stating, "We are encouraged by the SEC's recommendation and remain committed to advancing Suvorexant through the final stages of clinical development. With our robust R&D infrastructure and GMP-compliant manufacturing capabilities, we are confident in our ability to deliver high-quality, impactful CNS solutions to patients worldwide."

About Suvorexant

Suvorexant is a prescription medication designed to treat insomnia in adults. It works by modulating the sleep-wake cycle through the central nervous system, promoting improved sleep onset and maintenance.

Market Response

The market responded positively to this development, with Bajaj Healthcare shares closing at ₹482.60, up 0.62%.

Company Overview

Aspect	Details
Establishment	1993
Specialization	Manufacturing of intermediates, APIs, formulations & Nutraceuticals
Facilities	State-of-art manufacturing facilities for APIs, intermediates, and formulations
Global Presence	Europe, USA, Australia, Middle East, and South America

This approval marks a significant step for Bajaj Healthcare in addressing unmet medical needs in chronic and lifestyle-related disorders, particularly in the field of neurology. The company's focus on developing innovative solutions in the pharmaceutical sector continues to drive its growth and market position.